Kairos Therapeutics, Zymeworks deal

Kairos granted Zymeworks an exclusive option to merge in exchange for an undisclosed equity investment in Kairos. Kairos, which spun out of Canada’s Centre for Drug Research and Development (Vancouver, B.C.), develops next-generation antibody-drug conjugates for cancer. ...